Hip Joint Replacements
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Hip Replacement article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Dr Sarah Jarvis, 30th March 2022
This article has been archived and has not been updated since it was last reviewed. In March 2022, NICE produced new Quality Standard statements on primary replacement of hip, knee and shoulder. These have not been incorporated into the article below - please see full details in the reference link.
The quality statements relevant for adult hip replacement are:
- Patients planned for hip or knee replacement should be given advice on pre-operative rehabilitation when they are listed for surgery.
- Tranexamic acid should be given to adults having hip or knee replacement during surgery.
- There should be two 'stop moments' during hip replacement surgery to check implant details and the compatibility of all components.
- Before discharge following surgery, the patient should be given advice on postoperative rehabilitation.
Hip joint replacement (hip arthroplasty) is the surgical replacement of all, or part, of the hip joint with an artificial device. It can allow considerable improvement in pain and disability for the patient and has become one of the most successful innovations in modern medicine.
One review found that patients with hip osteoarthritis reported positive outcomes from hip arthroscopy. Patients with hip osteoarthritis had inferior results compared with those who did not. More severe chondropathy and patient age were associated with a higher risk and more rapid progression to total hip arthroplasty.
The procedure can be either a total hip arthroplasty or a hemiarthroplasty.
Total hip arthroplasty
The articular surfaces of the femur and the acetabulum are replaced. This can be:
- Conventional total hip arthroplasty - replacement of the femoral head and neck.
- Resurfacing total hip arthroplasty - replacement of the surface of the femoral head.
Hemiarthroscopy may be:
- Unipolar hemiarthroplasty - replacement of the femoral head and neck.
- Bipolar hemiarthroplasty - replacement of the femoral head and neck plus an addition of an acetabular cup that is not attached to the pelvis (ie fits into the existing acetabular cup).
- Resurfacing hemiarthroplasty - replacement of the surface of the femoral head.
A number of surgical approaches to the hip joint are used, each with different advantages and disadvantages. The most commonly used approaches include the direct anterior, direct lateral and posterior approaches.
- The number of hip arthroplasties is increasing with 76,500 in 2012 in the UK, a 7% increase compared to 2011.[5, 6]
- The percentage of total hip arthroplasties being performed on patients younger than 60 is increasing steadily.
Total hip arthroplasty
- Pain and disability due to degenerative or inflammatory arthritis in the hip joint, where non-operative management has failed and quality of life is being significantly interfered with.
- Fracture of the proximal femur.
- A resurfacing total hip arthroplasty may be considered in a young person with osteoarthritis and good bone stock (the advantage is that the femoral neck is preserved which may be advantageous if a later conventional arthroplasty is needed).
Usually indicated for patients with a femoral neck fracture who meet the following criteria:
- Poor general health or frailty.
- Pathological hip fracture.
- Severe osteoporosis.
- Inadequate closed reduction.
- Displaced fracture that is several days old.
- Pre-existing hip disease (eg, rheumatoid arthritis, avascular necrosis).
- Neurological disease.
- It is essential to ascertain that the hip is the site of the pathology, as pain in the hip can originate from other sites such as the knee or back. Replacing a hip that is not the cause of the pain will be of no value.
- Total hip replacement should not be undertaken lightly in a younger patient, as they tend to wear out the prosthesis due to a longer and more active life. Revision is much more substantial than the primary operation.
- Adequate quadriceps and other muscles around the joint are essential for rehabilitation. Poor muscles and neurological disease around the joint may be a contra-indication to surgery. The patient must be physically and mentally able to take part in rehabilitation.
When to refer to secondary care
- Most people with osteoarthritis of the hip are managed in primary care.
- The question is when to refer to an orthopaedic surgeon. (The need for immediate admission of a patient with a fractured hip is clear.)
- The British Orthopaedic Association suggests that local referral pathways should be drawn up giving criteria for referral.
- Referral may be based on a locally developed explicit scoring system. This may take into account factors such as the extent to which the condition is causing pain, disability, sleeplessness, loss of independence, inability to undertake normal activities, reduced functional capacity or psychiatric illness.
- A pre-admission assessment should take place within six weeks of the operation in secondary care.
- This should include identification of comorbidities and routine pre-operative investigations. However, general health screening should be carried out by the GP before referral to secondary care.
- Information about the operation should be given to the patient, including risks and possible complications. Written supportive information should be given.
- Fully informed consent should be obtained.
- Provisional discharge planning should take place.
Choice of device and surgical technique
Prostheses for total hip replacement and resurfacing arthroplasty are recommended by the National Institute for Health and Care Excellence (NICE) as treatment options for people with end-stage arthritis of the hip only if the prostheses have rates (or projected rates) of revision of 5% or less at 10 years.
- There are many different types of device available for joint replacement surgery. Materials used include metal, polyethylene and ceramic. Various methods of fixation include polymethylmethacrylate (PMMA) cement, screw fixation, cementless press fit and porous ingrowth fixation.
- The simplest and most commonly used classification is whether prostheses are:
- Hybrid (a cemented stem with a cementless cup).
- The surgeon may have a preference for an individual implant depending on factors including their training and consultant colleagues' preference.
- Patient factors including age and underlying health and comorbidities may also influence choice of device, eg ease of revision is needed in young patients.
- Cemented prostheses: these are thought to make up 90-95% of the UK total hip replacement market. NICE supports and suggests their use. (Although some evidence exists that these guidelines are not being followed.) They tend to fix well and early mobilisation is usually possible. There is the possibility of a foreign body reaction to the cement, which can affect the surrounding bone.
- Uncemented prostheses: these are generally easier to revise (an advantage in younger people who may outlive the prosthesis) but may take longer to fix and full mobilisation/weight bearing is not possible as early.
- NICE also suggests that more evidence of the performance of hip prostheses over longer periods of follow-up is required. The National Joint Registry will help this.
Metal-on-metal hip resurfacing arthroplasty
- In this procedure, the damaged surfaces of the femoral head and the acetabulum are removed and resurfaced: a metal cup in the acetabulum and a metal surface for the femoral head.
- Metal-on-metal hip resurfacing was developed for younger, active patients as an alternative to total hip arthroplasty but it remains controversial.
- Revisions and re-operations are more frequent and occur earlier with metal-on-metal hip resurfacing.
Clinical Editor's notes (July 2017)
Dr Hayley Willacy has read updated advice from the MHRA to assist the early detection of soft tissue reactions in patients implanted with metal-on-metal (MoM) hip replacements. The majority of patients with MoM hip replacements currently have well-functioning hips. However, some patients will develop progressive soft tissue reactions to the wear debris associated with MoM articulations. Orthopaedic experts have observed that soft tissue necrosis may occur in both asymptomatic and symptomatic patients, and believe early detection of these events should give a better revision outcome should this becomes necessary. This guidance contains detailed advice regarding monitoring and investigation of this cohort of patients, including rising blood metal levels indicating potential soft tissue reaction.
Minimally invasive hip replacement surgery
- NICE supports the use of single mini-incision hip replacement. Fluoroscopic guidance and computer-assisted navigation tools may be used. Benefits may include less tissue trauma, less blood loss and less pain. Appropriate training of the clinician is required and data should be submitted to the National Joint Registry.
- Guidance was also issued by NICE on minimally invasive two-incision surgery for total hip replacement. They confirm the procedure is safe but should be offered by suitably trained surgeons able to offer patients conventional hip replacements and with normal arrangements for clinical governance, consent and audit. Again data should be submitted to the National Joint Registry.
Postoperative care and rehabilitation
- Mobilisation postoperatively should include input from a physiotherapy team. Specific advice should be given to the patient about what they can and cannot do.
- Patients should only be discharged when they are considered capable of managing in the environment of their destination.
- Contact telephone numbers in case of problems should be provided.
- Patients should undergo outpatient follow-up within eight weeks of the operation.
- Best practice minimum requirements for subsequent follow-up are at one, five and then each subsequent five years after operation. Clinical examination and X-rays should be carried out to assess for possible implant failure.
About 1 in 8 of all total hip replacements requires revision within 10 years; 60% of these are because of wear-related complications.
- Postoperative pain and constipation.
- Urinary tract infection or retention of urine: urinary catheterisation for the operation is routine and can lead to these.
- Thromboembolism: prophylaxis is routine but there is still a risk.
- Chest infection.
- Implant fracture.
- Dislocation of the hip: can occur at any stage but usually occurs early.
- Wound infection or dehiscence.
- Infection of the prosthesis: it may be necessary to remove the prosthesis.
- Heterotopic ossification: usually asymptomatic but bony ankylosis can occur.
- Mechanical loosening and failure of the prosthesis: can occur in the longer term; can present with pain.
- Particle disease: a foreign-body reaction to implant debris causes focal osteolysis.
After hemiarthroplasty :
- Fracture of the femur can occur.
- Painful hemiarthroplasty may require conversion to a total hip replacement.
Dr Sarah Jarvis, February 2019
A new systematic review and meta-analysis in the Lancet, involving 13,212 patients, reveals that prognosis for hip replacement has improved. Doctors can advise patients that in 58% of patients, hip replacements last for at least 25 years.
- The clinical effectiveness of a prosthesis can be assessed by looking at:
- The persistence of pain and immobility.
- The proportion of total hip replacements that require revision within a specific period.
- About 80% of people get a good result, with improved mobility and loss of pain.
- The whole team, including surgeons, nurses, physiotherapists and occupational therapists, contributes to the overall success of total hip replacement.
- The 30-day mortality rate after elective total hip replacement is about 0.5%.[18, 19]
- After an arthroplasty for a fractured hip, the 30-day mortality rate is 2.4%.
- A 3% prevalence of prosthetic loosening is seen at 11 years.
- There is a 1% prevalence of prosthetic infection.
History of hip joint replacement
- In 1923, Dr. Marius Smith-Peterson of Massachusetts General Hospital used a glass cup to cover and reshape an arthritic femoral head. The original glass cup failed but it led to the development of similarly-shaped implants of strong and durable plastic, followed by metal materials. Subsequently, metallic femoral devices with anatomically-sized heads and variable femoral stems were developed.
- Many surgeons and bio-engineers contributed to the concepts, techniques and designs of implants for total hip replacement but the name most associated with early hip joint replacement is Sir John Charnley. He reported his experience with a steel femoral component and a plastic socket cup in 1961. He also revolutionised the field with the use of the self-curing acrylic cement used to fix the implants into the bone. These advances greatly improved the success rate of total hip replacement. The Charnley concepts of the hip implants are still in use today to a large extent. He came from Manchester, was born in 1911 and died in 1982.
- Dr Austin T Moore (1899-1963) was an orthopaedic surgeon in South Carolina. He performed one of the first total hip replacements in 1940 but it was the hemiarthroplasty to which he lent his name. He first performed this in 1942.
Further reading and references
Joint replacement (primary): hip, knee and shoulder; NICE Quality standard, March 2022
Primary Total Hip Replacement: A Guide to Best Practice; British Orthopaedic Association (2012)
Kemp JL, MacDonald D, Collins NJ, et al; Hip arthroscopy in the setting of hip osteoarthritis: systematic review of outcomes and progression to hip arthroplasty. Clin Orthop Relat Res. 2015 Mar473(3):1055-73. doi: 10.1007/s11999-014-3943-9. Epub 2014 Sep 18.
Petis S, Howard JL, Lanting BL, et al; Surgical approach in primary total hip arthroplasty: anatomy, technique and clinical outcomes. Can J Surg. 2015 Apr58(2):128-39.
Di Puccio F, Mattei L; Biotribology of artificial hip joints. World J Orthop. 2015 Jan 186(1):77-94. doi: 10.5312/wjo.v6.i1.77. eCollection 2015 Jan 18.
Liu XW, Zi Y, Xiang LB, et al; Total hip arthroplasty: areview of advances, advantages and limitations. Int J Clin Exp Med. 2015 Jan 158(1):27-36. eCollection 2015.
Hemiarthroplasty of the Hip; Wheeless' Textbook of Orthopaedics
Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty; NICE Technology Appraisal Guidance, February 2014
Roberts VI, Esler CN, Harper WM; What impact have NICE guidelines had on the trends of hip arthroplasty since their publication? The results from the Trent Regional Arthroplasty Study between 1990 and 2005. J Bone Joint Surg Br. 2007 Jul89(7):864-7.
Marshall DA, Pykerman K, Werle J, et al; Hip resurfacing versus total hip arthroplasty: a systematic review comparing standardized outcomes. Clin Orthop Relat Res. 2014 Jul472(7):2217-30. doi: 10.1007/s11999-014-3556-3. Epub 2014 Apr 4.
Medical Device Alert; All metal-on-metal (MoM) hip replacements: updated advice for follow-up of patients MHRA (June 2017)
Single mini-incision surgery for total hip replacement; NICE Interventional Procedure Guidance, 2006
Minimally invasive total hip replacement; NICE Interventional Procedure Guidance, October 2010
Bradberry SM, Wilkinson JM, Ferner RE; Systemic toxicity related to metal hip prostheses. Clin Toxicol (Phila). 2014 Sep-Oct52(8):837-47. doi: 10.3109/15563650.2014.944977. Epub 2014 Aug 16.
Vrgoc G, Japjec M, Gulan G, et al; Periprosthetic infections after total hip and knee arthroplasty--a review. Coll Antropol. 2014 Dec38(4):1259-64.
Lie SA, Engesaeter LB, Havelin LI, et al; Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand. 2002 Aug73(4):392-9.
Mahomed NN, Barrett JA, Katz JN, et al; Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am. 2003 Jan85-A(1):27-32.
Parvizi J, Ereth MH, Lewallen DG; Thirty-day mortality following hip arthroplasty for acute fracture. J Bone Joint Surg Am. 2004 Sep